KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Change in Cash (2016 - 2025)

Historic Change in Cash for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $8.1 million.

  • Supernus Pharmaceuticals' Change in Cash rose 13972.37% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.1 million, marking a year-over-year increase of 29135.08%. This contributed to the annual value of -$5.7 million for FY2024, which is 6832.17% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Change in Cash of $8.1 million as of Q3 2025, which was up 13972.37% from $28.9 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Change in Cash registered a high of $369.1 million during Q1 2023, and its lowest value of -$437.5 million during Q2 2023.
  • Moreover, its 5-year median value for Change in Cash was -$11.7 million (2024), whereas its average is -$7.1 million.
  • Data for Supernus Pharmaceuticals' Change in Cash shows a peak YoY increase of 52075.26% (in 2023) and a maximum YoY decrease of 85805.1% (in 2023) over the last 5 years.
  • Over the past 5 years, Supernus Pharmaceuticals' Change in Cash (Quarter) stood at -$11.8 million in 2021, then plummeted by 55.08% to -$18.4 million in 2022, then fell by 8.49% to -$19.9 million in 2023, then soared by 288.94% to $37.7 million in 2024, then crashed by 78.46% to $8.1 million in 2025.
  • Its Change in Cash was $8.1 million in Q3 2025, compared to $28.9 million in Q2 2025 and $46.5 million in Q1 2025.